Gufic Biosciences Limited
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufact… Read more
Gufic Biosciences Limited (GUFICBIO) - Total Liabilities
Latest total liabilities as of September 2025: ₹6.40 Billion INR
Based on the latest financial reports, Gufic Biosciences Limited (GUFICBIO) has total liabilities worth ₹6.40 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Gufic Biosciences Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Gufic Biosciences Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Gufic Biosciences Limited Competitors by Total Liabilities
The table below lists competitors of Gufic Biosciences Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cognor S.A.
WAR:COG
|
Poland | zł1.60 Billion |
|
Pro-Dex Inc
NASDAQ:PDEX
|
USA | $20.62 Million |
|
Accsys Technologies PLC
PINK:ACSYF
|
USA | $104.69 Million |
|
Tiziana Life Sciences Ltd
NASDAQ:TLSA
|
USA | $7.40 Million |
|
OBOOK Holdings Inc. Class A Common Shares
NASDAQ:OWLS
|
USA | $30.60 Million |
|
Sonaecom S.G.P.S. S.A
STU:XOA1
|
Germany | €41.77 Million |
|
Quirin Privatbank AG
F:QB7
|
Germany | €1.06 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Gufic Biosciences Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.19 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gufic Biosciences Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gufic Biosciences Limited (2006–2025)
The table below shows the annual total liabilities of Gufic Biosciences Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹5.68 Billion | +1.48% |
| 2024-03-31 | ₹5.60 Billion | +9.08% |
| 2023-03-31 | ₹5.13 Billion | +103.48% |
| 2022-03-31 | ₹2.52 Billion | +15.40% |
| 2021-03-31 | ₹2.19 Billion | -21.41% |
| 2020-03-31 | ₹2.78 Billion | +36.24% |
| 2019-03-31 | ₹2.04 Billion | +11.85% |
| 2018-03-31 | ₹1.83 Billion | +29.35% |
| 2017-03-31 | ₹1.41 Billion | +19.36% |
| 2016-03-31 | ₹1.18 Billion | +18.02% |
| 2015-03-31 | ₹1.00 Billion | +17.96% |
| 2014-03-31 | ₹849.37 Million | +26.43% |
| 2013-03-31 | ₹671.83 Million | +23.01% |
| 2012-03-31 | ₹546.14 Million | +29.53% |
| 2011-03-31 | ₹421.61 Million | +10.56% |
| 2010-03-31 | ₹381.33 Million | +23.73% |
| 2009-03-31 | ₹308.19 Million | -5.81% |
| 2008-03-31 | ₹327.18 Million | -13.39% |
| 2007-03-31 | ₹377.78 Million | -3.94% |
| 2006-03-31 | ₹393.28 Million | -- |